Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.
Maiken Cavling Arendrup,Maiken Cavling Arendrup,Anupam Prakash,Joseph Meletiadis,Joseph Meletiadis,Cheshta Sharma,Anuradha Chowdhary +6 more
Reads0
Chats0
TLDR
CLISI and EUCAST MICs were remarkably similar and confirmed uniform fluconazole resistance and variable acquired resistance to the other agents and various methods for epidemiological cutoff determinations.Abstract:
Candida auris is an emerging multidrug-resistant yeast. So far, all but two susceptibility testing studies have examined ≤50 isolates, mostly with the CLSI method. We investigated CLSI and EUCAST MICs for 123 C. auris isolates and eight antifungals and evaluated various methods for epidemiological cutoff (ECOFF) determinations. MICs (in milligrams per liter) were determined using CLSI method M27-A3, and the EUCAST E.Def 7.3. ANOVA analysis of variance with Bonferroni's multiple-comparison test and Pearson analysis were used on log2 MICs (significance at P values of 2). The ECOFFs (in milligrams per liter) were similar across the three different methods for itraconazole (ranges for CLSI/EUCAST, 0.25 to 0.5/0.5 to 1), posaconazole (0.125/0.125 to 0.25), amphotericin B (0.25 to 0.5/1 to 2), micafungin (0.25 to 0.5), and anidulafungin (0.25 to 0.5/0.25 to 1). In contrast, the estimated ECOFFs were dependent on the method applied for voriconazole (1 to 32) and isavuconazole (0.125 to 4). CLSI and EUCAST MICs were remarkably similar and confirmed uniform fluconazole resistance and variable acquired resistance to the other agents.read more
Citations
More filters
Journal ArticleDOI
Candida auris: a Review of the Literature.
Anna Jeffery-Smith,Surabhi K. Taori,Silke Schelenz,Katie Jeffery,Elizabeth M. Johnson,Andrew M. Borman,Rohini Manuel,Colin S Brown,Colin S Brown +8 more
TL;DR: Genetic analysis indicates the simultaneous emergence of separate clades of this organism in different geographical locations, which will provide direction for further work in this field of Candida auris.
Journal ArticleDOI
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.
Anuradha Chowdhary,Anupam Prakash,Cheshta Sharma,Milena Kordalewska,Anil Kumar,Smita Sarma,Bansidhar Tarai,Ashutosh Singh,Gargi Upadhyaya,Shalini Upadhyay,Priyanka Yadav,Pradeep Kumar Singh,Vikas Khillan,Neelam Sachdeva,David S. Perlin,Jacques F. Meis +15 more
TL;DR: The antifungal susceptibility of C. auris isolates from 10 hospitals in India collected over a period of 8 years was studied, finding that 25% and 13% of isolates were MDR and multi-azole resistant, respectively.
Journal ArticleDOI
Candida auris: an Emerging Fungal Pathogen.
TL;DR: This minireview details the global emergence of C. auris and discusses issues relevant to clinical microbiology laboratories, hospital infection control, and antimicrobial stewardship efforts.
Journal ArticleDOI
Candida auris: Epidemiology, biology, antifungal resistance, and virulence.
TL;DR: Difficulty in its identification, multidrug resistance properties, evolution of virulence factors, associated high mortality rates in patients, and long-term survival on surfaces in the environment make C. auris particularly problematic in clinical settings.
Journal ArticleDOI
Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Johanna Rhodes,Alireza Abdolrasouli,Rhys A. Farrer,Christina A. Cuomo,David M. Aanensen,Darius Armstrong-James,Matthew C. Fisher,Silke Schelenz +7 more
TL;DR: Multiple differential episodic selection of antifungal resistant genotypes has occurred within a genetically heterogenous population across this outbreak, creating a resilient pathogen and making it difficult to define local-scale patterns of transmission and implement outbreak control measures.
References
More filters
Journal ArticleDOI
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart,Kizee A. Etienne,Snigdha Vallabhaneni,Joveria Farooqi,Anuradha Chowdhary,Nelesh P. Govender,Arnaldo Lopes Colombo,Belinda Calvo,Christina A. Cuomo,Christopher A. Desjardins,Elizabeth L. Berkow,Mariana Castanheira,Rindidzani E. Magobo,Kauser Jabeen,Rana Jawad Asghar,Jacques F. Meis,Brendan R Jackson,Tom Chiller,Anastasia P. Litvintseva +18 more
TL;DR: Candida auris is an emerging healthcare-associated pathogen associated with high mortality, and WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents.
Journal ArticleDOI
Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital
TL;DR: A single strain of a novel ascomycetous yeast species belonging to the genus Candida was isolated from the external ear canal of an inpatient in a Japanese hospital and indicated that this strain represents a new species with a close phylogenetic relationship to Candida ruelliae and Candida haemulonii in the Metschnikowiaceae clade.
Book
Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement
John H. Rex,Clinical +1 more
TL;DR: The Quality Management System Approach will be used as a guide for the selection of Antifungal Agents for Broth Dilution Susceptibility Tests.
Journal ArticleDOI
Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method
Shallu Kathuria,Pradeep Kumar Singh,Cheshta Sharma,Anupam Prakash,Aradhana Masih,Anil Kumar,Jacques F. Meis,Anuradha Chowdhary +7 more
TL;DR: A cautionary approach is recommended for laboratories relying on commercial systems for identification and antifungal susceptibility testing of rare yeasts, as 90% of the isolates characterized by commercial identification systems are misidentified as C. auris.
Journal ArticleDOI
First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
TL;DR: The first three cases of nosocomial fungemia caused by C. auris are described, which confirms that it is a causative agent of bloodstream infections and emphasizes the importance of accurately identifying this species.
Related Papers (5)
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart,Kizee A. Etienne,Snigdha Vallabhaneni,Joveria Farooqi,Anuradha Chowdhary,Nelesh P. Govender,Arnaldo Lopes Colombo,Belinda Calvo,Christina A. Cuomo,Christopher A. Desjardins,Elizabeth L. Berkow,Mariana Castanheira,Rindidzani E. Magobo,Kauser Jabeen,Rana Jawad Asghar,Jacques F. Meis,Brendan R Jackson,Tom Chiller,Anastasia P. Litvintseva +18 more